PTPA and colorectal carcinoma: These findings could have a potential therapeutic relevance since FTY720, a PP2A-activating drug that binds and blocks SET [28], has recently shown to resensitize CRC cell to cetuximab [29] and our results suggest that miR-199b could be playing a role via SET regulation.